Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer (Q40715310)
Jump to navigation
Jump to search
scientific article published on 6 June 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer |
scientific article published on 6 June 2016 |
Statements
1 reference
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer (English)
1 reference
Christophe Massard
1 reference
Michael S Gordon
1 reference
Sunil Sharma
1 reference
Saeed Rafii
1 reference
Zev A Wainberg
1 reference
Jason Luke
1 reference
Tyler J Curiel
1 reference
Gerardo Colon-Otero
1 reference
Omid Hamid
1 reference
Rachel E Sanborn
1 reference
Peter H O'Donnell
1 reference
Alexandra Drakaki
1 reference
Winston Tan
1 reference
John F Kurland
1 reference
Marlon C Rebelatto
1 reference
Xiaoping Jin
1 reference
John A Blake-Haskins
1 reference
Ashok Gupta
1 reference
Neil H Segal
1 reference
6 June 2016
1 reference
1 reference
34
1 reference
26
1 reference
3119-3125
1 reference
Identifiers
1 reference
1 reference
1 reference